Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660309 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT00660309 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 45 participants.
The verdict
NCT00660309, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or irbesartan on renal blood flow, glomerular filtration rate, and retinal blood flow in patients with type 2 diabetes mellitus.
Interventions
- DRUG Irbesartan
- DRUG Aliskiren
- DRUG Captopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660309
The ClinicalTrials.gov registry entry for NCT00660309 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Irbesartan is the first listed.
NCT00660309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00660309 about?
NCT00660309 is a clinical study titled "A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus". The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or irbesartan on renal blood flow, glomerular filtration rate, and retinal blo...
What is the current status of trial NCT00660309?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2008-04. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00660309?
The interventions under investigation include: Irbesartan (DRUG), Aliskiren (DRUG), Captopril (DRUG).
Who is sponsoring clinical trial NCT00660309?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.